Tag
major depressive disorder
- Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial
- Pharma giant AbbVie to spend over US$1B on Gilgamesh's lead psychedelic
- One dose of psilocybin can alleviate depression for 5 years, U.S. researchers find
- Gilgamesh's psychedelic drug demonstrates exceptional efficacy for treating depression
- Cybin receives FDA approval for new in‑human clinical trial
- Field Trip white paper makes strong health and business case for ketamine therapy